Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

TransMedics Group (NASDAQ: TMDX) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August. Unfortunately, shares of the healthcare stock ...

TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (“OCS”) technology. The optimism, led by solid third-quarter 2025 results, ...

TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.

Leading organ transplant technology provider TransMedics (NASDAQ: TMDX) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth ...

TransMedics Group's Organ Care System (OCS) is transforming organ transplantation. The company should be well-positioned to dominate the organ transplant market for decades. TransMedics believes it ...

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion ...

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc (NASDAQ:TMDX), accusing the organ transplant technology company of fraudulent practices, including kickbacks, ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...

TransMedics continues to lock in its status as the leader in organ transplant technology. Josh Kohn-Lindquist is a contributing Motley Fool stock market analyst covering consumer goods, industrials, ...